Production of the Russian Smallpox Drug “NIOCH-14” May Start in the Spring of 2026
This is the first chemical drug in Russia intended for the treatment and emergency prevention of smallpox and other orthopoxvirus infections, including mpox.
R-Pharm Import-Substitutes German Erbitux — Drug for Head and Neck Cancer Therapy
The Ministry of Health of the Russian Federation has...
Petrovax Pharm Investments in Meningitis Vaccine Production Exceed 3 Billion Rubles
Biopharmaceutical company Petrovax Pharm has announced receiving an expanded...
Ellara Prepares to Launch Unique Peptide Synthesis Facility
Pharmaceutical company Ellara is completing preparations for the opening...
GMP Registry: New Certificates Issued and Refusals in January 2026
On January 26, the Ministry of Industry and Trade...
Eli Lilly and Nvidia Launch LillyPod — The Most Powerful AI Supercomputer in Global Pharma
On February 25, 2026, pharmaceutical giant Eli Lilly officially...
EMA is Looking for a New Director. The Most Prestigious Vacancy in European Pharmaceuticals Has Opened
On February 20, 2026, the race for one of...
Top Ten Most Anticipated Drug Launches of 2026 That Will Reshape the Global Market
Experts from Evaluate forecast a record year for the...
An “AI Pill” for Indian Pharma: Sun Pharma and Glenmark Change the Rules of the Game
The Indian pharmaceutical industry, long known as the "pharmacy of the world" due to its generic drug production, is beginning a technological transformation.
2025’s Top 10 Clinical Trial Flops in Global Pharma
Clinical trials are always high-stakes gambles. 2025 has been...
Rospotrebnadzor Cleans Up the Web: 3,000 Resources with Dangerous Dietary Supplements Blocked
The Federal Service for Surveillance on Consumer Rights Protection...
Automated Fines for Expired Dietary Supplements to Start March 1 for Pharmacies
The dietary supplement (BAA) market will be the first...
EMA and PIC/S Tighten Control Over Active Pharmaceutical Substance Production
The European Medicines Agency (EMA), in collaboration with the...
What Happens in 2031? Regulator Sets “Deadline” for EAEU Veterinary Drug Rules
Since March 2024, supranational rules for the circulation of...
Transition to EAEU Standards: GMP Certification Rules for Veterinary Drugs are Changing
A draft Decree of the Government of the Russian...
Eli Lilly and Nvidia Launch LillyPod — The Most Powerful AI Supercomputer in Global Pharma
On February 25, 2026, pharmaceutical giant Eli Lilly officially...
An “AI Pill” for Indian Pharma: Sun Pharma and Glenmark Change the Rules of the Game
The Indian pharmaceutical industry, long known as the "pharmacy of the world" due to its generic drug production, is beginning a technological transformation.
SUSU Scientists Synthesize a Selective Anti-Anxiety Molecule
Researchers at South Ural State University (SUSU) have discovered...
Neural Network Breakthrough: FDA Approves Trials for AI-Created Parkinson’s Drug
January 23, 2026, became a landmark date for digital...
Good AI Practice: EMA and FDA Establish 10 Global Principles
Global regulators are setting a unified standard for the...
Production of the Russian Smallpox Drug “NIOCH-14” May Start in the Spring of 2026
This is the first chemical drug in Russia intended for the treatment and emergency prevention of smallpox and other orthopoxvirus infections, including mpox.
R-Pharm Import-Substitutes German Erbitux — Drug for Head and Neck Cancer Therapy
The Ministry of Health of the Russian Federation has...
Petrovax Pharm Investments in Meningitis Vaccine Production Exceed 3 Billion Rubles
Biopharmaceutical company Petrovax Pharm has announced receiving an expanded...
Ellara Prepares to Launch Unique Peptide Synthesis Facility
Pharmaceutical company Ellara is completing preparations for the opening...
GMP Registry: New Certificates Issued and Refusals in January 2026
On January 26, the Ministry of Industry and Trade...
Eli Lilly and Nvidia Launch LillyPod — The Most Powerful AI Supercomputer in Global Pharma
On February 25, 2026, pharmaceutical giant Eli Lilly officially...
EMA is Looking for a New Director. The Most Prestigious Vacancy in European Pharmaceuticals Has Opened
On February 20, 2026, the race for one of...
Top Ten Most Anticipated Drug Launches of 2026 That Will Reshape the Global Market
Experts from Evaluate forecast a record year for the...
An “AI Pill” for Indian Pharma: Sun Pharma and Glenmark Change the Rules of the Game
The Indian pharmaceutical industry, long known as the "pharmacy of the world" due to its generic drug production, is beginning a technological transformation.
2025’s Top 10 Clinical Trial Flops in Global Pharma
Clinical trials are always high-stakes gambles. 2025 has been...
Rospotrebnadzor Cleans Up the Web: 3,000 Resources with Dangerous Dietary Supplements Blocked
The Federal Service for Surveillance on Consumer Rights Protection...
Automated Fines for Expired Dietary Supplements to Start March 1 for Pharmacies
The dietary supplement (BAA) market will be the first...
EMA and PIC/S Tighten Control Over Active Pharmaceutical Substance Production
The European Medicines Agency (EMA), in collaboration with the...
What Happens in 2031? Regulator Sets “Deadline” for EAEU Veterinary Drug Rules
Since March 2024, supranational rules for the circulation of...
Transition to EAEU Standards: GMP Certification Rules for Veterinary Drugs are Changing
A draft Decree of the Government of the Russian...
Eli Lilly and Nvidia Launch LillyPod — The Most Powerful AI Supercomputer in Global Pharma
On February 25, 2026, pharmaceutical giant Eli Lilly officially...
An “AI Pill” for Indian Pharma: Sun Pharma and Glenmark Change the Rules of the Game
The Indian pharmaceutical industry, long known as the "pharmacy of the world" due to its generic drug production, is beginning a technological transformation.
SUSU Scientists Synthesize a Selective Anti-Anxiety Molecule
Researchers at South Ural State University (SUSU) have discovered...
Neural Network Breakthrough: FDA Approves Trials for AI-Created Parkinson’s Drug
January 23, 2026, became a landmark date for digital...
Good AI Practice: EMA and FDA Establish 10 Global Principles
Global regulators are setting a unified standard for the...
PHARMPROM is a premier digital resource for the pharmaceutical sector, combining breaking news, deep insights, and key market events. We cover the entire product lifecycle—from R&D and manufacturing to distribution—in strict accordance with Good Pharmaceutical Practices (GxP).
Disclaimer All content on pharmprom.net is for informational purposes only and does not constitute medical advice. The materials are intended exclusively for industry professionals and are not addressed to the general public.
Headlines
Eli Lilly and Nvidia Launch LillyPod — The Most Powerful AI Supercomputer in Global Pharma
On February 25, 2026, pharmaceutical giant Eli Lilly officially...
NL Continent LLC to Launch a Large Dietary Supplement Production Complex in Novosibirsk
On February 27, 2026, the Department of Architectural and...
Innovative GMP Laboratory for R-Pharm Talent Development Opens in Yaroslavl
On February 27, 2026, the N.P. Pastukhov Yaroslavl Industrial...
GMP Registry Update: 8 New Certificates by the End of February 2026
In late February, the registry was updated with entries for production sites from four countries: Russia, France, Italy, and Germany. A total of 8 sites received positive decisions.
